P663 Efficacy of tofacitinib in patients with ulcerative colitis after previous ineffective biological therapies
ECCO'20 Vienna
2020
P664 The impact of vedolizumab on extra-intestinal manifestations in inflammatory bowel disease patients: A real-life experience of a single-centre cohort
ECCO'20 Vienna
2020
P665 Which second-line biologic after anti-TNF failure during Crohn’s disease: Ustekinumab or vedolizumab, a multicentre retrospective study
ECCO'20 Vienna
2020
P666 Neutropenia in inflammatory bowel disease patients on TNF inhibitors: A single-centre, retrospective cohort study
ECCO'20 Vienna
2020
P667 Combined therapy of perianal fistulas with autologous adipose-derived stem cells
ECCO'20 Vienna
2020
P668 Real-life comparison of different anti-TNF biologic therapies for ulcerative colitis treatment: A retrospective cohort study
ECCO'20 Vienna
2020
P669 Adherence to self-administered biologic therapies in inflammatory bowel disease: Experience in a tertiary hospital
ECCO'20 Vienna
2020
P670 Usefulness of monitoring the concentration of azathioprine metabolites in the children with inflammatory bowel disease and autoimmune hepatitis
ECCO'20 Vienna
2020
P671 Natural history and clinical outcomes of patients with ulcerative colitis who are intolerant to 5-aminosalicylic acid agents: A multi-centre cohort study
ECCO'20 Vienna
2020
P672 The escalation of therapy or intervention (ETI) calculator for ulcerative colitis: does it have the potential to help outpatient capacity meet demand?
ECCO'20 Vienna
2020
P673 Strategy of selecting anti-TNF agent in patients with Crohn’s disease: A multi-centre retrospective cohort study by the Osaka gut forum
ECCO'20 Vienna
2020
P674 Monitoring posologic change in adalimumab intensification dosing regimen from 40 mg every week to 80 mg every other week
ECCO'20 Vienna
2020
P676 Faecal monitoring is useful in monitoring treatment response in anti-TNF-treated patients
ECCO'20 Vienna
2020
P677 It’s time to grow up: what is it like to transition from the paediatric to adult inflammatory bowel disease service?
ECCO'20 Vienna
2020
P678 Effect of accelerated infliximab induction on short-term outcomes of paediatric acute severe ulcerative colitis
ECCO'20 Vienna
2020
P679 What is the best strategy after failure to anti-TNF? Ustekinumab or other anti-TNF?
ECCO'20 Vienna
2020